Published in JAMA on January 20, 1999
2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ (2007) 9.10
The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring) (2006) 8.25
A two-year randomized trial of obesity treatment in primary care practice. N Engl J Med (2011) 5.98
Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci (2010) 3.72
Long-term drug treatment for obesity: a systematic and clinical review. JAMA (2014) 3.69
Treatment of obesity in primary care practice in the United States: a systematic review. J Gen Intern Med (2009) 2.89
Randomized clinical trials of weight loss maintenance: a review. J Cardiovasc Nurs (2008) 2.43
Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg (2003) 1.83
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA (2016) 1.78
Anti-Obesity Drugs: A Review about Their Effects and Safety. Diabetes Metab J (2012) 1.66
Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis. CMAJ Open (2014) 1.58
Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev (2009) 1.46
IQP-VV-102, a Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety. Evid Based Complement Alternat Med (2015) 1.36
Industry funding and the reporting quality of large long-term weight loss trials. Int J Obes (Lond) (2008) 1.32
2014 clinical practice guidelines for overweight and obesity in Korea. Endocrinol Metab (Seoul) (2014) 1.27
Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol (2010) 1.20
Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther (2013) 1.09
Rapid response predicts binge eating and weight loss in binge eating disorder: findings from a controlled trial of orlistat with guided self-help cognitive behavioral therapy. Behav Res Ther (2007) 1.07
Pharmacotherapy for obesity. JAMA (1999) 1.03
Obesity: an overview on its current perspectives and treatment options. Nutr J (2004) 0.99
Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. PLoS One (2012) 0.96
Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab (2004) 0.96
Extracts from "Clinical Evidence". Obesity. BMJ (2001) 0.93
Maintenance of weight loss in adolescents: current status and future directions. J Obes (2011) 0.93
Non alcoholic fatty liver disease: a clinical approach and review. Can J Gastroenterol (2006) 0.92
A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovasc Dis (2016) 0.92
Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut (2007) 0.88
Effectiveness of weight loss interventions for obese older adults. Am J Health Promot (2013) 0.87
A natural fiber complex reduces body weight in the overweight and obese: a double-blind, randomized, placebo-controlled study. Obesity (Silver Spring) (2013) 0.87
Effectiveness of a psychosocial weight management program for individuals with schizophrenia. J Behav Health Serv Res (2014) 0.87
Obesity: a review of pathogenesis and management strategies. Can J Gastroenterol (2008) 0.86
Orlistat. No hurry.... Can Fam Physician (1999) 0.86
Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers. Br J Clin Pharmacol (2008) 0.86
Predictive significance of changes in dietary restraint in obese patients with binge eating disorder during treatment. Int J Eat Disord (2010) 0.85
Diabetes Dyslipidemia. Diabetes Ther (2016) 0.85
New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). J Diabetes Complications (2013) 0.84
Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as. Behav Res Ther (2013) 0.84
Effects of the 5-HT2C receptor agonist meta-chlorophenylpiperazine on appetite, food intake and emotional processing in healthy volunteers. Psychopharmacology (Berl) (2014) 0.84
Present and future: pharmacologic treatment of obesity. J Obes (2011) 0.84
Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). Dig Dis Sci (2007) 0.83
Treating obesity. Lost cause or new opportunity? Can Fam Physician (2000) 0.82
acp Best Practice No 168. The investigation and management of obesity. J Clin Pathol (2003) 0.82
Effects of a stimulant-free dietary supplement on body weight and fat loss in obese adults: a six-week exploratory study. Curr Ther Res Clin Exp (2003) 0.82
The use of serotonergic drugs to treat obesity--is there any hope? Drug Des Devel Ther (2011) 0.82
The use of lorcaserin in the management of obesity: a critical appraisal. Drug Des Devel Ther (2010) 0.81
Frequent Self-Weighing and Visual Feedback for Weight Loss in Overweight Adults. J Obes (2015) 0.81
Strategies for weight maintenance in adult populations treated for overweight and obesity: a systematic review and meta-analysis. CMAJ Open (2015) 0.80
The appropriateness of routine medication treatment for schizophrenia. Schizophr Bull (2008) 0.80
Clinical and economic considerations of antiobesity treatment: a review of orlistat. Clinicoecon Outcomes Res (2010) 0.80
Metabolic syndrome in the Mediterranean region: Current status. Indian J Endocrinol Metab (2012) 0.80
Treatment of clozapine-associated weight gain: a systematic review. Eur J Clin Pharmacol (2015) 0.80
Analysis of the factors affecting the success of weight reduction programs. Yonsei Med J (2007) 0.79
Evaluation of efficacy and safety of orlistat in obese patients. Indian J Endocrinol Metab (2011) 0.79
Receptivity to Bariatric Surgery in Qualified Patients. J Obes (2016) 0.79
Preventive pharmacotherapy in type 2 diabetes mellitus. Indian J Endocrinol Metab (2012) 0.79
The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort. Br J Clin Pharmacol (2015) 0.79
Impact of orlistat-induced weight loss on diastolic function and heart rate variability in severely obese subjects with diabetes. J Obes (2010) 0.78
Orlistat in the prevention of diabetes in the obese patient. Vasc Health Risk Manag (2008) 0.78
Regulation of appetite to treat obesity. Expert Rev Clin Pharmacol (2011) 0.77
Current and novel approaches to the drug therapy of obesity. Eur J Clin Pharmacol (2006) 0.77
Effects of a weight-reduction program with orlistat on serum leptin levels in obese women: A 12-week, randomized, placebo-controlled study. Curr Ther Res Clin Exp (2004) 0.77
Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity. Expert Rev Endocrinol Metab (2010) 0.76
Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome. Core Evid (2008) 0.76
Tackling obesity: new therapeutic agents for assisted weight loss. Diabetes Metab Syndr Obes (2010) 0.76
Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers of Trials of Orlistat: A Document Analysis. PLoS Med (2016) 0.76
Antiobesity pharmacotherapy for patients with type 2 diabetes: focus on long-term management. Endocrinol Metab (Seoul) (2014) 0.76
Efficacy and safety of canagliflozin in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Medicine (Baltimore) (2016) 0.76
Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes. J Clin Med (2014) 0.75
Perioperative optimization of patients undergoing bariatric surgery. J Obes (2012) 0.75
Association between weight control failure and suicidal ideation in overweight and obese adults: a cross-sectional study. BMC Public Health (2016) 0.75
Randomised, double-blind, clinical investigation to compare orlistat 60 milligram and a customized polyglucosamine, two treatment methods for the management of overweight and obesity. BMC Obes (2017) 0.75
Does orlistat cause acute kidney injury? Ther Adv Drug Saf (2012) 0.75
Intestinal removal of free fatty acids from hosts by Lactobacilli for the treatment of obesity. FEBS Open Bio (2016) 0.75
Tools for Successful Weight Management in Primary Care. Am J Med Sci (2015) 0.75
Orlistat associated with hypertension. Digit preference lays conclusions about orlistat open to doubt. BMJ (2001) 0.75
Outdated and misleading review of orlistat. Can Fam Physician (1999) 0.75
Anti-Tumorigenic Potential of a Novel Orlistat-AICAR Combination in Prostate Cancer Cells. J Cell Biochem (2017) 0.75
NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry (2000) 19.37
Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol (1998) 10.23
Body mass index as a measure of adiposity among children and adolescents: a validation study. J Pediatr (1998) 9.66
Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med (2000) 8.47
Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. N Engl J Med (1992) 7.45
How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol (1996) 7.12
Viral clearance without destruction of infected cells during acute HBV infection. Science (1999) 6.78
Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr (2000) 5.29
Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J Appl Physiol (1985) (2000) 5.24
Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol (1985) (1998) 5.01
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr (1999) 4.15
Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature (1992) 4.12
Rising tide of cardiovascular disease in American Indians. The Strong Heart Study. Circulation (1999) 3.82
Height-normalized indices of the body's fat-free mass and fat mass: potentially useful indicators of nutritional status. Am J Clin Nutr (1990) 3.78
Organ-tissue mass measurement allows modeling of REE and metabolically active tissue mass. Am J Physiol (1998) 3.65
Appendicular skeletal muscle mass: effects of age, gender, and ethnicity. J Appl Physiol (1985) (1997) 3.63
Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A (1998) 3.46
Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet (2000) 3.44
Alternative treatments for weight loss: a critical review. Crit Rev Food Sci Nutr (2001) 3.43
Sequence-dependent correction of random coil NMR chemical shifts. J Am Chem Soc (2001) 3.42
Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol (1985) (2000) 3.31
Body composition estimates from NHANES III bioelectrical impedance data. Int J Obes Relat Metab Disord (2002) 3.16
The biology of white adipocyte proliferation. Obes Rev (2001) 2.94
Human body composition and the epidemiology of chronic disease. Obes Res (1995) 2.93
Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. Am J Clin Nutr (1983) 2.89
Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res (2001) 2.85
Total-body skeletal muscle mass: development and cross-validation of anthropometric prediction models. Am J Clin Nutr (2000) 2.71
Why treatments for obesity don't last. J Am Diet Assoc (1991) 2.68
Statistical considerations regarding the use of ratios to adjust data. Int J Obes Relat Metab Disord (1995) 2.59
Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J (2001) 2.55
Cardiovascular disease risk factors among American Indians. The Strong Heart Study. Am J Epidemiol (1995) 2.53
Larger amounts of visceral adipose tissue in Asian Americans. Obes Res (2001) 2.50
Complete genome sequence of the genetically tractable hydrogenotrophic methanogen Methanococcus maripaludis. J Bacteriol (2004) 2.47
Anthropometric measurement of muscle mass: revised equations for calculating bone-free arm muscle area. Am J Clin Nutr (1982) 2.41
Effects of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab (1996) 2.40
Is blockade of pancreatic lipase the answer? Am J Clin Nutr (1999) 2.34
Diabetes and impaired glucose tolerance in three American Indian populations aged 45-74 years. The Strong Heart Study. Diabetes Care (1995) 2.26
Distinct mechanisms for the activation of the RSK kinases/MAP2 kinase/pp90rsk and pp70-S6 kinase signaling systems are indicated by inhibition of protein synthesis. Cell Growth Differ (1991) 2.16
Dual-energy X-ray absorptiometry body composition model: review of physical concepts. Am J Physiol (1996) 2.15
Coronary heart disease prevalence and its relation to risk factors in American Indians. The Strong Heart Study. Am J Epidemiol (1995) 2.12
Alterations of the stalk of the influenza virus neuraminidase: deletions and insertions. Virus Res (1993) 2.12
Accurate measurement of liver, kidney, and spleen volume and mass by computerized axial tomography. Ann Intern Med (1979) 2.11
Hydration of fat-free body mass: new physiological modeling approach. Am J Physiol (1999) 2.09
NMR structural and dynamic characterization of the acid-unfolded state of apomyoglobin provides insights into the early events in protein folding. Biochemistry (2001) 2.07
Weight stability masks sarcopenia in elderly men and women. Am J Physiol Endocrinol Metab (2000) 2.05
Mutations of the gene encoding the transmembrane transporter protein ABC-C6 cause pseudoxanthoma elasticum. J Mol Med (Berl) (2000) 2.04
Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology (2011) 1.99
Can ethnic differences in men's preferences for women's body shapes contribute to ethnic differences in female adiposity? Obes Res (1993) 1.97
Chromatin structure and gene expression. Proc Natl Acad Sci U S A (1996) 1.93
Effect of unplanned extubation on outcome of mechanical ventilation. Am J Respir Crit Care Med (2000) 1.87
Bone turnover and density in obese premenopausal women during moderate weight loss and calcium supplementation. J Bone Miner Res (2001) 1.86
Validity of methods of body composition assessment in young and older men and women. J Appl Physiol (1985) (1999) 1.82
Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology (2005) 1.80
New bioimpedance analysis system: improved phenotyping with whole-body analysis. Eur J Clin Nutr (2004) 1.79
Evidence for prospective associations among depression and obesity in population-based studies. Obes Rev (2011) 1.78
IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways. Am J Physiol Lung Cell Mol Physiol (2001) 1.78
Are dual-energy X-ray absorptiometry regional estimates associated with visceral adipose tissue mass? Int J Obes Relat Metab Disord (2002) 1.77
Resting metabolic rate in obese, premenopausal black women. Am J Clin Nutr (1997) 1.76
Cardiac abnormalities in cachectic patients before and during nutritional repletion. Am Heart J (1978) 1.75
The five-level model: a new approach to organizing body-composition research. Am J Clin Nutr (1992) 1.73
Relation of diet to high-density-lipoprotein cholesterol in middle-aged marathon runners, joggers, and inactive men. N Engl J Med (1980) 1.72
Can a weight loss of one pound a week be achieved with a 3500-kcal deficit? Commentary on a commonly accepted rule. Int J Obes (Lond) (2013) 1.70
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Measurement of liver and spleen volume by computed tomography. Assessment of reproducibility and changes found following a selective distal splenorenal shunt. Radiology (1981) 1.65
p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J Biol Chem (1999) 1.65
Stenting from the vertebral artery to the posterior inferior cerebellar artery. AJNR Am J Neuroradiol (2011) 1.64
Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene (2008) 1.64
Retraction. Darsee JR, Heymsfield SB. Decreased myocardial taurine levels and hypertaurinuria in a kindred with mitral-valve prolapse and congestive cardiomyopathy. N Engl J Med 1981;304:129-35. N Engl J Med (1983) 1.63
Dietary modulation of omega-3/omega-6 polyunsaturated fatty acid ratios in patients with breast cancer. J Natl Cancer Inst (1997) 1.62
A comparison of surgeons' posture during laparoscopic and open surgical procedures. Surg Endosc (1997) 1.62
Differences in skeletal muscle and bone mineral mass between black and white females and their relevance to estimates of body composition. Am J Clin Nutr (1992) 1.61
Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care (1998) 1.58
Skeletal muscle mass: evaluation of neutron activation and dual-energy X-ray absorptiometry methods. J Appl Physiol (1985) (1996) 1.57
Bioimpedance analysis: evaluation of leg-to-leg system based on pressure contact footpad electrodes. Med Sci Sports Exerc (1997) 1.57
LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. Arterioscler Thromb Vasc Biol (2000) 1.56
Prediction of glucose response to weight loss in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med (1990) 1.56
In vivo protective performance of N95 respirator and surgical facemask. Am J Ind Med (2006) 1.56
Habitual dietary intake and insulin sensitivity in lean and obese adults. Am J Clin Nutr (1992) 1.56
Hydration of fat-free body mass: review and critique of a classic body-composition constant. Am J Clin Nutr (1999) 1.55
Use of dual-energy x-ray absorptiometry in body-composition studies: not yet a "gold standard". Am J Clin Nutr (1993) 1.54
Standardization of nomenclature of body composition in weight loss. Am J Clin Nutr (1997) 1.54
Trans-acting elements modulate expression of the human c-myc gene in Burkitt lymphoma cells. Proc Natl Acad Sci U S A (1986) 1.53
Nutrition training in graduate medical (residency) education: a survey of selected training programs. Am J Clin Nutr (1991) 1.53
Weighing the options: criteria for evaluating weight-management programs. The Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity. Obes Res (1995) 1.52
A comparative study of different means of assessing long-term energy expenditure in humans. Am J Physiol (1996) 1.52
MRI-measured bone marrow adipose tissue is inversely related to DXA-measured bone mineral in Caucasian women. Osteoporos Int (2006) 1.52
Regulation of pp90rsk phosphorylation and S6 phosphotransferase activity in Swiss 3T3 cells by growth factor-, phorbol ester-, and cyclic AMP-mediated signal transduction. Mol Cell Biol (1991) 1.51
Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med (2000) 1.51
Development of malabsorption and nutritional complications in simian immunodeficiency virus-infected rhesus macaques. AIDS (1994) 1.51
Prevalence of adult-onset IDDM in the U.S. population. Diabetes Care (1994) 1.51
Smaller organ tissue mass in the elderly fails to explain lower resting metabolic rate. Ann N Y Acad Sci (2000) 1.50
Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The Strong Heart Study. Diabetes Care (1998) 1.49
A human proinsulin variant at arginine 65. Nature (1981) 1.49
Why do individuals not lose more weight from an exercise intervention at a defined dose? An energy balance analysis. Obes Rev (2012) 1.47
Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev (2009) 1.46
Retraction. Darsee JR, Heymsfield SB, Nutter DO. Hypertrophic cardiomyopathy and human leukocyte antigen linkage: differentiation of two forms of hypertrophic cardiomyopathy. N Engl J Med 1979;300:877-82,. N Engl J Med (1983) 1.45
Challenges in obesity management. South Med J (1998) 1.45